DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $563,000 | +1.4% | 2,500 | 0.0% | 0.07% | 0.0% |
| Q4 2020 | $555,000 | +3.2% | 2,500 | 0.0% | 0.07% | -10.4% |
| Q3 2020 | $538,000 | +21.7% | 2,500 | 0.0% | 0.08% | +6.9% |
| Q2 2020 | $442,000 | +27.7% | 2,500 | 0.0% | 0.07% | +2.9% |
| Q1 2020 | $346,000 | -54.9% | 2,500 | -50.0% | 0.07% | -25.5% |
| Q4 2019 | $767,000 | +6.2% | 5,000 | 0.0% | 0.09% | -9.6% |
| Q3 2019 | $722,000 | -32.6% | 5,000 | -33.3% | 0.10% | -29.3% |
| Q2 2019 | $1,072,000 | +8.3% | 7,500 | 0.0% | 0.15% | +0.7% |
| Q1 2019 | $990,000 | -36.0% | 7,500 | -50.0% | 0.15% | +20.7% |
| Q4 2018 | $1,546,000 | +42.2% | 15,000 | +50.0% | 0.12% | -5.5% |
| Q3 2018 | $1,087,000 | +10.1% | 10,000 | 0.0% | 0.13% | +3.2% |
| Q2 2018 | $987,000 | +0.8% | 10,000 | 0.0% | 0.12% | -3.9% |
| Q1 2018 | $979,000 | +5.5% | 10,000 | 0.0% | 0.13% | +5.7% |
| Q4 2017 | $928,000 | +8.2% | 10,000 | 0.0% | 0.12% | +4.3% |
| Q3 2017 | $858,000 | +1.7% | 10,000 | 0.0% | 0.12% | -3.3% |
| Q2 2017 | $844,000 | -1.3% | 10,000 | 0.0% | 0.12% | -9.7% |
| Q1 2017 | $855,000 | +9.9% | 10,000 | 0.0% | 0.13% | +4.7% |
| Q4 2016 | $778,000 | -0.8% | 10,000 | 0.0% | 0.13% | +1.6% |
| Q3 2016 | $784,000 | -22.4% | 10,000 | 0.0% | 0.13% | -25.0% |
| Q2 2016 | $1,010,000 | +6.4% | 10,000 | 0.0% | 0.17% | +3.1% |
| Q1 2016 | $949,000 | +2.2% | 10,000 | 0.0% | 0.16% | +12.4% |
| Q4 2015 | $929,000 | +9.0% | 10,000 | 0.0% | 0.14% | +3.6% |
| Q3 2015 | $852,000 | -0.5% | 10,000 | 0.0% | 0.14% | +8.5% |
| Q2 2015 | $856,000 | +0.8% | 10,000 | 0.0% | 0.13% | +8.4% |
| Q1 2015 | $849,000 | -0.9% | 10,000 | 0.0% | 0.12% | -4.8% |
| Q4 2014 | $857,000 | +12.8% | 10,000 | 0.0% | 0.12% | +7.8% |
| Q3 2014 | $760,000 | -3.4% | 10,000 | 0.0% | 0.12% | 0.0% |
| Q2 2014 | $787,000 | +4.9% | 10,000 | 0.0% | 0.12% | +6.4% |
| Q1 2014 | $750,000 | -2.8% | 10,000 | 0.0% | 0.11% | 0.0% |
| Q4 2013 | $772,000 | +11.4% | 10,000 | 0.0% | 0.11% | +3.8% |
| Q3 2013 | $693,000 | +9.5% | 10,000 | 0.0% | 0.10% | -6.2% |
| Q2 2013 | $633,000 | – | 10,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |